Roche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its repertoire. The three drug discovery deals are with Convelo Therapeutics in neurological ...

Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked ...

Canada’s Parvus Therapeutics has signed a deal with Roche’s Genentech unit to develop, manufacture and market drugs for inflammatory bowel disease, autoimmune liver diseases, and coeliac disease.

Roche has avoided large acquisitions since the Genentech deal but has supplemented in-house innovation with bolt-on acquisitions and collaborations in both pharmaceuticals and diagnostics over the ...

Genentech, a member of Roche (RHHBY), announced that the FDA has accepted the company’s supplemental biologics license application, or sBLA, for Columvi in combination with gemcitabine and ...

M.D., Ph.D., global head of pharma partnering at Roche. “Ribometrix has built capabilities to drug-specific RNAs, and we look forward to a productive collaboration to explore this emerging area of ...

Genentech, a member of Roche (RHHBY), announced topline results from the overall survival analysis of the Phase III INAVO120 study investigating Itovebi in combination with palbociclib and ...

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics ...